dr. daud on dabrafenib/trametinib vs immunotherapy in melanoma
Published 4 years ago • 753 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
1:14
dr. daud on the combinations of immunotherapy for melanoma
-
1:36
dr. daud on the challenges of treating metastatic melanoma with braf inhibitor monotherapy
-
1:28
immunotherapy versus targeted therapy for advanced melanoma
-
2:15
dr. daud discusses the immunogenicity of melanoma
-
2:33
dr. sullivan discusses role of dabrafenib plus trametinib in melanoma
-
1:52
dr. long on dabrafenib/trametinib in braf v600e-mutant melanoma
-
2:16
dr. rodabe n. amaria on dabrafenib plus trametinib in melanoma
-
1:24
dr. algazi on benefit of continuous dabrafenib/trametinib dosing in braf melanoma
-
1:08
dr. weber on dabrafenib/trametinib versus vemurafenib/cobimetinib in melanoma
-
0:44
dr. michael rotkowitz on dabrafenib and trametinib combination side effects
-
1:27
bgb324 with pembrolizumab or dabrafenib/trametinib in melanoma
-
1:04
dr. wilson on long-term data with dabrafenib plus trametinib in melanoma
-
2:19
dr. robert on 5-year analysis of dabrafenib/trametinib in braf v600-mutant melanoma
-
1:53
dr. daud on challenges facing the treatment landscape for melanoma
-
2:11
dr. georgina long on dabrafenib and trametinib in braf-mutated melanoma
-
0:30
dr. postow on fda approval of adjuvant dabrafenib plus trametinib in braf-mutant melanoma
-
1:32
adil daud, md: optimal sequencing for braf-mutant melanoma patients
-
1:11
dr. weber on the fda approval of adjuvant dabrafenib/trametinib in braf-mutant melanoma
-
0:48
dr. michael rotkowitz on the dabrafenib plus trametinib combination for melanoma